Welcome to the e-CCO Library!

DOP045: Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel Disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Carlsen*1, 2, C. Jakobsen2, L. F. Hansen2, A. Paerregaard2, T. Kallemose3, G. Houen4, L.B. Riis5, P. S. Munkholm6, V. Wewer2

Created: Friday, 22 February 2019, 9:49 AM
DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hart A., Li K., Gasink C., Jacobstein D., Brodmerkel C.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Hart A.
Genetic factors, Pharmacogenetics, Ustekinumab
Files: 1
DOP046: Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Berends1,2*, M. Löwenberg2, F. Baert3, R. Mathôt1, E. Clasquin2, C. Van Der Woude4, F. Hoentjen5, P. Bossuyt6, D. Franchimont7, T. Rispens8,9, A. De Vries9, S. Vermeire10, G. D'Haens2

Created: Thursday, 21 February 2019, 9:14 AM
DOP046: Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1 189 patients with Crohns disease: a multicentre cohort study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. Tanaka*1, N. Kamata2, A. Yamada3, K. Endo4, T. Fujii5, T. Yoshino6, 7, T. Sugaya8, Y. Yokoyama9, S. Bamba10, J. Umeno11, Y. Yanai12, M. Ishii13, T. Kawaguchi14, S. Shinzaki15, Y. Toya16, T. Kobayashi17, M. Nojima18, T. Hibi17

Created: Friday, 22 February 2019, 9:49 AM
DOP047: Early fibrostenosis in Crohn's disease is associated with multiple susceptibility loci on Immunochip analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Holvoet T.*1, Bossuyt P.2,3, Cleynen I.3, De Kock I.4, Hindryckx P.1, Vermeire S.3,5, Laukens D.1, De Vos M.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP047: Early fibrostenosis in Crohn’s Disease is associated with multiple susceptibility loci on Immunochip analysis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Holvoet T.
Genetic factors, Fibrosis, Genetics
Files: 1
DOP047: Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Dreesen1*, G. D'Haens2, F. Baert3, B. Pariente4, Y. Bouhnik5, J. vander Woude6, J. Moreau7, D. Laharie8, S. Vermeire9,10, A. Gils1

Created: Thursday, 21 February 2019, 9:14 AM
DOP047: PYRAMID registry: an observational study of adalimumab in Crohns disease—results at year 7
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens1, W. Reinisch*2, J. Satsangi3, E. Loftus Jr4, R. Panaccione5, H. Read6, M. Heinrich7, J. Petersson6, A.M. Robinson6

Created: Friday, 22 February 2019, 9:49 AM
DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 7
Year: 2016
Source: ECCO'16 DOP
Authors: Reinisch W.
anti-TNF agents, Crohn's Disease
Files: 1
DOP048: Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome—post-hoc analyses from the PURSUIT programme
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J.-F. Colombel*1, W. Reinisch2, P. Gibson3, W. J. Sandborn4, B. Feagan5, S. Xu6, R. Strauss6, H. Zhang6, D. Tarabar7, Z. Hebzda8, P. Rutgeerts9, C. Marano6

Created: Friday, 22 February 2019, 9:49 AM
DOP048: PROFILE trial: predicting outcomes for Crohn's disease using a molecular biomarker
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lee J.1,2, Biasci D.1, Noor N.*1,2, McKinney E.1, Ahmad T.3,4, Lewis N.5, Hart A.6,7, Lyons P.1, Parkes M.1,2, Smith K.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP048: PROFILE trial: Predicting outcomes for Crohn’s Disease using a molecular biomarker
Year: 2017
Source: ECCO'17 Barcelona
Authors: Noor N.
Natural history, Genetics, T cell
Files: 1
DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Yarur1*, A. Bruss1, C. Fox1, P. Beniwal-Patel1, A. Patel1, B. Berens1, S. Naik2, D. Stein1

Created: Thursday, 21 February 2019, 9:14 AM
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Tarabar1*, K. El Jurdi2, O. Yvellez2, Z. Milenkovic1, S. Petrovic1, B. Subotic1, T.P. Brocic1, I. Brcerevic1, O. Latinovic3, D.T. Rubin2

Created: Thursday, 21 February 2019, 9:14 AM
DOP049: Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Probert*1, D. R. Gaya2, P. J. Hamlin3, P. Irving4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6

Created: Friday, 22 February 2019, 9:49 AM